PRESS RELEASE published on 10/21/2024 at 07:30, 1 month ago THIRD-QUARTER 2024 SALES FORVIA reports strong Q3 2024 sales of €6.4bn, outperforming by 420bps despite challenging automotive market conditions. Focus on sustainable growth and deleveraging Sustainability Automotive Market Deleveraging Forvia Q3 2024 Sales
BRIEF published on 09/27/2024 at 07:35, 1 month 24 days ago FORVIA Adjusts FY 2024 Guidance Amid Market Uncertainties Operating Margin Guidance Sales Forecast Forvia Debt Ratio
PRESS RELEASE published on 09/27/2024 at 07:30, 1 month 24 days ago FORVIA FY 2024 guidance update FORVIA adjusts 2024 guidance due to lower production outlook and uncertain environment. Initiatives accelerated to improve 2025 performance in a challenging environment. Key target of net debt/adj. EBITDA ratio < 1.5x at end-2025 remains unchanged 2024 Guidance Deleveraging Forvia Production Outlook Uncertain Environment
BRIEF published on 09/05/2024 at 18:35, 2 months 15 days ago FORVIA: Total number of voting rights and shares as of August 31, 2024 Euronext Paris Share Capital Voting Rights Actions Forvia
PRESS RELEASE published on 09/05/2024 at 18:30, 2 months 15 days ago FORVIA: Total number of voting rights and shares forming the share capital Nanterre, 5 September 2024 - Total number of voting rights and shares forming the share capital for a company listed on Euronext Paris revealed Euronext Paris Share Capital Voting Rights ISIN Code Nanterre
BRIEF published on 09/03/2024 at 09:55, 2 months 18 days ago Templeton Global Advisors reduces stake in Forvia AMF Stock Market Threshold Crossing Forvia Templeton Global Advisors
BRIEF published on 08/05/2024 at 08:35, 3 months 16 days ago FORVIA: Total Number of Voting Rights and Shares for 2024 Euronext Paris Voting Rights Shares Forvia Faurecia
PRESS RELEASE published on 08/05/2024 at 08:30, 3 months 16 days ago FORVIA: Total number of voting rights and shares forming the share capital Press release regarding the total number of voting rights and shares forming the share capital of a company traded on Euronext Paris Euronext Paris Share Capital Voting Rights French Financial Markets Authority ISIN Code
BRIEF published on 07/25/2024 at 09:03, 3 months 27 days ago FORVIA Releases Updated Financial Report for First Half of 2024 Investors Financial Report French Autorité Des Marchés Financiers Forvia First Half 2024
PRESS RELEASE published on 07/25/2024 at 08:58, 3 months 27 days ago CANCEL AND REPLACE - AVAILABILITY OF THE FINANCIAL REPORT FOR THE FIRST HALF OF 2024 FORVIA releases new version of Financial report for first half of 2024, filed with French Autorité des marchés financiers, available on company website. Updates replace previous version Investors Financial Report Update French Autorité Des Marchés Financiers Forvia
Published on 11/21/2024 at 14:15, 15 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 30 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 30 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 30 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 14 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 15 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 55 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 32 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 10 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 45 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 45 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
